NAMPT Inhibitors Market, Distribution by Type of Molecule (Small Molecules and Biologics), Therapeutic Area (Oncological and Respiratory Disorders), Indication (Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Acute Respiratory Distress Syndrome, and Acute Myeloid Leukemia), Route of Administration (Oral and Intravenous), Line of Treatment (1st Line and 2nd Line), and Key Geographical Regions (North America, Europe, Asia and Rest of the World): Industry Trends and Global Forecasts, 2022-2040

  • Lowest Price Guaranteed From USD 5,899

  • Published
    September 2022

  • Slides
    141

  • View Count
    592

Example Insights

NAMPT-Inhibitors-Market-Context-thumb NAMPT-Inhibitors-Market-List-of-Drug-Candidates-thumb NAMPT-Inhibitors-Market-Pipeline-Review-thumb NAMPT-Inhibitors-Market-Competitiveness-Analysis-thumb NAMPT-Inhibitors-Market-Partnerships-and-Collaborations-thumb
NAMPT-Inhibitors-Market-Fundings-and-Investments-thumb NAMPT-Inhibitors-Market-Grants-Analysis-thumb NAMPT-Inhibitors-Market-Publication-Analysis-thumb NAMPT-Inhibitors-Market-Global-Events-Analysis-thumb NAMPT-Inhibitors-Market-Social-Media-Analysis-thumb
NAMPT-Inhibitors-Market-Drug-Failure-Analysis-thumb NAMPT-Inhibitors-Market-FDA-Approval-Strategies-thumb NAMPT-Inhibitors-Market-Product-wise-Forecast-thumb    

Overview

The NAMPT inhibitor developed during our research can be used to target inflammatory disorders, metabolic disorders and oncological disorders. Importantly, our compound has been studied in the preclinical stages, for the treatment of pancreatic cancer

-- Former Research Associate, an India-based mid-sized company

Globally, cancer is one of the leading causes of death; in 2020, about 10 million cancer related deaths were reported. Further, according to a study published in American Cancer Society Journal, by 2040, the number of cancer cases is projected to reach over 28 million, indicating a cumulative growth of nearly 47%, since 2020. The continuous growth in the number of cancer patients imposes a huge burden, in terms of finances as well as resources, on  the overall healthcare system. In this context, it is worth mentioning that the annual expenditure associated with cancer care is more than USD 200 billion, in the US alone. Given the fact that majority of the current treatment options for cancer have proven to be inadequate, especially for late-stage cancers, there is a high demand for highly effective therapeutics. Over time, many research studies have demonstrated that NAMPT (Nicotinamide Phosphoribosyl Transferase) can interfere with the metabolism of NAD+, which is known to be the fuel for tumor cells; this notion has encouraged several researchers to conduct extensive studies for the development of novel and efficacious drug candidates, such as NAMPT inhibitors.

NAMPT inhibitors are being evaluated to target a wide range of indications, primarily focusing on oncological disorders. Given the encouraging research outcomes, the domain has attracted the attention of many private and public investors who have made investments worth more than USD 650 million, since 2018. Driven by the increasing R&D activity, promising clinical data and financial support from investors, the NAMPT inhibitors market is anticipated to grow at a commendable pace in the mid to long-term.

Scope of the Report

The “NAMPT Inhibitors Market, Distribution by Type of Molecule (Small Molecules and Biologics), Therapeutic Area (Oncological and Respiratory Disorders), Indication (Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Acute Respiratory Distress Syndrome, and Acute Myeloid Leukemia), Route of Administration (Oral and Intravenous), Line of Treatment (1st Line and 2nd Line), and Key Geographical Regions (North America, Europe, Asia and Rest of the World): Industry Trends and Global Forecasts, 2022-2035” report features an extensive study of the current landscape, offering an informed opinion on the likely adoption of NAMPT inhibitors in the healthcare domain, till 2040. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this market space. Amongst other elements, the report includes:

  • A brief introduction to important concepts related to NAMPT inhibitors, featuring information on key historical events, key indications targeted by such therapeutics, potential concerns associated with their use and mechanism of action. This chapter further features details related to the recent advancements that have been made in the NAMPT inhibitors market.
  • A detailed overview of the current market landscape of NAMPT targeting drug candidates that are currently being researched in pre-clinical and clinical studies, featuring an elaborate analysis of such therapies based on several relevant parameters, such as phase of development (preclinical, phase I, phase I/II and phase II), type of molecule (small molecules and biologics), route of administration (oral and intravenous), target indication (acute myeloid leukemia, acute respiratory distress syndrome, hodgkin lymphoma, and non-hodgkin lymphoma), line of treatment (1st line and 2nd line) and type of therapy (monotherapy and combination therapy). 
  • An elaborate analysis of recent partnerships and collaborations that have been inked by several stakeholders engaged in the domain of NAMPT inhibitors since 2022, including a brief description of the various partnership models adopted (including product development and commercialization agreement, product development, manufacturing and commercialization agreement, mergers and research and development agreement).
  • An insightful analysis of recent funding instances that have been reported by several players engaged in the NAMPT inhibitors domain, including details on the year of funding, amount received and type of funding (awards / grants, venture series, initial public offering, secondary offerings, debt financing and other equity).
  • An in-depth analysis on various grants, since the year 2022, received by players engaged in this field based on year of award, amount awarded, funding institute, activity code, focus area, recipient organizations, support period, type of grant application, and prominent program officers.
  • An insightful company competitiveness analysis of NAMPT inhibitor targeting therapy developers, based on several relevant parameters, such as the firm’s portfolio strength (taking into consideration number of drugs in pipeline, phase of development and type of molecule), partnership strength (in terms of the number of partnerships established and partnership year) and funding strength (in terms of number of funding instances, amount of funding, year of funding, type of funding and number of lead investors).
  • Elaborate profiles of prominent players that are engaged in the development of NAMPT inhibitors, featuring a brief overview of the company, along with information on financials, product portfolio, patent portfolio, recent developments and an informed future outlook.
  • A detailed analysis of several peer-reviewed, scientific articles related to research on NAMPT inhibitors, over last 12 years, based on several relevant parameters, such as year of publication, type of publication and popular keywords.
  • An analysis of the global events attended by industry players, based on several relevant parameters, such as year of event, event platform, type of event, leading presenters (in terms of number of participations) and leading players (in terms of number of participations).
  • An analysis of prevalent and emerging trends related to NAMPT inhibitors as represented on the social media platform, Twitter, based on several relevant parameters, such as year of tweet, top users and emerging focus areas.
  • An in-depth analysis focused on NAMPT inhibitors that failed to progress to later stages of clinical development, based on various relevant parameters, such as phase of discontinuation, target indication, route of administration and type of molecule.
  • A proprietary analysis on various competitive strategies that can be implemented by drug developers engaged in this domain, to expedite the FDA approval process for their proprietary products; it includes information on several relevant parameters, such as clinical evidence, awards / grants, research findings, partnerships, other financial support received and others.
  • A detailed market forecast analysis, highlighting the likely growth of the NAMPT inhibitors in the healthcare market, over the period 2022-2040, based on several relevant parameters, such as target patient population, likely launch year of therapy candidates, approval timeline of drugs, likely price points and expected rates of adoption, across various geographical regions. The report also features the likely distribution of the current and forecasted opportunity related to NAMPT inhibitors market across type of molecule (small molecules and biologics), therapeutic area (oncological and respiratory disorders), indication (non-hodgkin lymphoma, hodgkin lymphoma, acute respiratory distress syndrome, and acute myeloid leukemia), route of administration (oral and intravenous), line of treatment (1st line and 2nd line), and key geographical regions (North America, Europe, Asia and Rest of the World).

Frequently Answered Questions

  • Who are the leading players engaged in the development of NAMPT inhibitors?
  • What types of partnership models are commonly adopted by industry stakeholders engaged in this industry?
  • Who are the key investors in the NAMPT inhibitors domain?
  • What is the evolving trend of publications focused on NAMPT inhibitors?
  • What are the prominent reasons for failure of such therapeutics in their respective clinical / preclinical studies?
  • What are the strategic initiatives undertaken by players engaged in this market space related to research and development of NAMPT inhibitors? 
  • What are the key value drivers that are likely to influence the evolution of this upcoming market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Contents

Table Of Contents

1. EXECUTIVE SUMMARY

2. INTRODUCTION
2.1. Overview of NAMPT Inhibitors
2.2. Key Historical Events Related to NAMPT Inhibitors
2.3. NAMPT Inhibitors: Recent Activity
2.4. NAMPT Inhibitors: Mechanism of Action
2.5. NAMPT Inhibitors: Key Target Indications

3. MARKET LANDSCAPE
3.1. NAMPT Inhibitors: Pipeline Review
3.1.1. Analysis by Phase of Development
3.1.2. Analysis by Type of Molecule
3.1.3. Analysis by Phase of Development and Type of Molecule
3.1.4. Analysis by Type of Therapy
3.1.5. Analysis by Line of Treatment
3.1.5. Analysis by Route of Administration

3.2. NAMPT Inhibitors: Developer Landscape
3.2.1. Analysis by Type of Player
3.2.2. Analysis by Year of Establishment
3.2.3. Analysis by Location of Headquarters
3.2.4. Analysis by Location of Headquarters and Stage of Development
3.2.5. Analysis by Location of Headquarters and Phase of Development
3.2.6. Analysis by Location of Headquarters and Type of Molecule

4. PARTNERSHIPS AND COLLABORATIONS
4.1. NAMPT Inhibitors: Partnerships and Collaborations
4.1.1. Analysis by Year of Partnership
4.1.2. Analysis by Type of Partnership
4.1.3. Analysis by Year and Type of Partnership
4.1.4. Analysis by Type of Agreement
4.1.5. Analysis by Intercontinental and Intracontinental Deals
4.1.6. Active Players: Analysis by Number of Partnerships

5. FUNDING AND INVESTMENTS
5.1. NAMPT Inhibitors: Funding and Investments
5.1.1. Analysis of Instances by Year
5.1.2. Analysis of Amount Raised by Year
5.1.3. Analysis of Number of Instances Year and Type of Funding
5.1.4. Analysis of Amount Raised by Year and Type of Funding
5.1.5. Analysis of Number of Instances by Type of Funding
5.1.6. Analysis of Amount Raised by Type of Funding
5.1.7. Most Active Investors: Analysis by Number of Funding Instances

5.1.8. Active Players: Analysis by Number of Instances
5.1.9. Active Players: Analysis by Amount Raised
5.1.10. Analysis of Instances by Geography
5.1.11. Analysis of Total Amount Raised by Geography
5.1.12. Analysis of Total Amount Raised by Year of Establishment
5.1.13. Concluding Remarks

6. GRANTS ANALYSIS
6.1. Scope and Methodology
6.2. NAMPT Inhibitors: List of Grants Awarded by National Institutes of Health
6.2.1. Analysis of Instances by Year
6.2.2. Analysis of Amount Awarded by Year
6.2.3. Popular Recipient Organizations: Analysis by Grant Amount
6.2.4. Prominent Program Officers: Analysis by Number of Grants
6.2.5. Analysis by Type of Recipient Organization
6.2.6. Analysis of Instances by Year
6.2.7. Analysis by Purpose of Grant Award
6.2.8. Analysis by Funding Institute
6.2.9. Analysis by Support Period
6.2.10. Analysis by Funding Institute and Support Period
6.2.11. Analysis by Activity Code
6.2.12. Analysis by Type of Application
6.2.13. Word Cloud of NIH Spending Categories

7. COMPANY COMPETITIVENESS
7.1. Key Assumptions and Parameters
7.2. Methodology
7.3. Benchmarking of Portfolio Strength
7.4. Benchmarking of Partnership Activity
7.5. Benchmarking of Funding Activity
7.6. Benchmarking of Portfolio Strength
7.7. NAMPT Inhibitors: Company Competitiveness Analysis

8. COMPANY PROFILES
8.1. Antengene Therapeutics
8.1.1. Company Overview
8.1.2. Funding Information
8.1.3. Product Portfolio
8.1.4. Recent Developments and Future Outlook

8.2. Aqualung Therapeutics
8.2.1. Company Overview
8.2.2. Funding Information
8.2.3. Product Portfolio
8.2.4. Patent Portfolio
8.2.5. Recent Developments and Future Outlook

8.3. Karyopharm Therapeutics
8.3.1. Company Overview
8.3.2. Financial Information
8.3.3. Product Portfolio
8.3.4. Patent Portfolio
8.3.5. Recent Developments and Future Outlook

8.4. OncoTartis
8.4.1. Company Overview
8.4.2. Funding Information
8.4.3. Product Portfolio
8.4.4. Patent Portfolio
8.4.5. Recent Developments and Future Outlook

8.5. Onxeo
8.5.1. Company Overview
8.5.2. Financial Information
8.5.3. Product Portfolio
8.5.4. Recent Developments and Future Outlook

9. PUBLICATION ANALYSIS
9.1. Methodology and Key Parameters
9.2. NAMPT Inhibitors: List of Publications
9.2.1. Analysis by Year of Publication
9.2.2. Analysis by Type of Publication
9.2.3. Most Popular Journals: Analysis by Number of Publications
9.2.4. Most Popular Publishers: Analysis by Number of Publications
9.2.5. Analysis by Journal Impact Factor
9.2.6. Most Popular Journals: Analysis by Journal Impact Factor
9.2.7. Analysis by Geography
9.2.8. Emerging Focus Areas

10. GLOBAL EVENTS ANALYSIS
10.1. Methodology and Key Parameters
10.2. NAMPT Inhibitors: List of Global Events
10.2.2. Cumulative Year-wise Trend
10.2.3. Analysis by Type of Event
10.2.4. Analysis by Event Platform
10.2.5. Leading Players: Analysis by Number of Participants
10.2.6. Leading Presenters: Analysis by Number of Participants
10.2.7. Analysis by Geography

11. SOCIAL MEDIA ANALYSIS
11.1. Methodology and Key Parameters
11.1.1. Cumulative Year-wise Activity
11.1.2. Leading Users: Analysis by Number of Tweets
11.1.3. Trending Words / Phrases on Twitter

12. DRUG FAILURE ANALYSIS
12.1. Methodology and Key Parameters
12.2. NAMPT Inhibitors: List of Failed Drug Candidates
12.2.1. Analysis by Phase of Discontinuation
12.2.2. Analysis by Trial Status
12.2.3. Analysis by Target Indication
12.2.4. Analysis by Route of Administration
12.2.5. Analysis by Type of Sponsor
12.2.6. Affiliated Stakeholders: Analysis by Number of Trials
12.2.7. Analysis by Reasons for Drug Failure
12.2.8. Key Terms in Study Results
12.2.9. Other Plausible Reasons for Drug Failure

13. FDA APPROVAL STRATEGIES
13.1. Methodology and Key Parameters
13.2. General Reasons for Failure of Trials Focused on NAMPT Inhibitors and Key Strategies Adopted by Developers
13.3. Drug Specific Business Models followed by Company
13.4. Analysis of Drug Candidates by Business Model

14. MARKET FORECAST AND OPPORTUNITY ANALYSIS
14.1. Key Assumptions and Parameters
14.2. Forecast Methodology
14.3. Global NAMPT Inhibitors Market, 2027-2040
14.4. List of Forecasted Drugs
14.4.1. OT-82, OncoTartis
14.4.1.1. Global Sales Forecast
14.4.1.2. Regional Sales Forecast
14.4.1.3. Net Present Value
14.4.1.4. Value Creation Analysis

14.4.2. ALT-100, Aqualung Therapeutics
14.4.2.1. Global Sales Forecast
14.4.2.2. Regional Sales Forecast
14.4.2.3. Net Present Value
14.4.2.4. Value Creation Analysis

14.4.3. ATG-019, Antengene Therapeutics
14.4.3.1. Global Sales Forecast
14.4.3.2. Regional Sales Forecast
14.4.3.3. Net Present Value
14.4.3.4. Value Creation Analysis

14.4.4. KPT-9274, Karyopharm Therapeutics
14.4.4.1. Global Sales Forecast
14.4.4.2. Regional Sales Forecast
14.4.4.3. Net Present Value
14.4.4.4. Value Creation Analysis

14.5. NAMPT Inhibitors Market: Analysis by Type of Molecule, 2027 and 2040
14.5.1. NAMPT Inhibitors Market for Small Molecules, 2027-2040
14.5.2. NAMPT Inhibitors Market for Biologics, 2029-2040

14.6. NAMPT Inhibitors Market: Analysis by Therapeutic Area, 2027 and 2040
14.6.1. NAMPT Inhibitors Market for Oncological Disorders, 2027-2040
14.6.2. NAMPT Inhibitors Market for Respiratory Disorders, 2029-2040

14.7. NAMPT Inhibitors Market: Analysis by Target Indication, 2027 and 2040
14.7.1. NAMPT Inhibitors Market for Non-Hodgkin Lymphoma, 2027-2040
14.7.2. NAMPT Inhibitors Market for Hodgkin Lymphoma, 2027-2040
14.7.3. NAMPT Inhibitors Market for Acute Respiratory Distress Syndrome, 2029-2040
14.7.4. NAMPT Inhibitors Market for Acute Myeloid Leukemia, 2033-2040

14.8. NAMPT Inhibitors Market: Analysis by Line of Treatment, 2027 and 2040
14.8.1. NAMPT Inhibitors Market for First Line Therapies, 2027-2040
14.8.2. NAMPT Inhibitors Market for Second Line Therapies, 2033-2040

14.9. NAMPT Inhibitors Market: Analysis by Route of Administration, 2027 and 2040
14.9.1. NAMPT Inhibitors Market for Oral Therapies, 2027-2040
14.9.2. NAMPT Inhibitors Market for Intravenous Therapies, 2029-2040

14.10. NAMPT Inhibitors: Market Share of Key Players
14.11. NAMPT Inhibitors Market: Analysis by Geography, 2030-2040

15. EXECUTIVE INSIGHTS

16. APPENDIX 1: LIST OF FIGURES

17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Distribution by Phase of Development
Figure 3.2 Distribution by Type of Molecule
Figure 3.3 Distribution by Phase of Development and Type of Molecule
Figure 3.4 Distribution by Type of Therapy
Figure 3.5 Distribution by Line of Treatment
Figure 3.6 Distribution by Route of Administration
Figure 3.7 Distribution by Type of Player
Figure 3.8 Distribution by Year of Establishment
Figure 3.9 Distribution by Company Size
Figure 3.10 Players in North America
Figure 3.11 Players in Europe
Figure 3.12 Players in Rest of the World
Figure 3.13 Distribution by Stage of Development and Location of Headquarters
Figure 3.14 Distribution by Type of Molecule and Location of Headquarters
Figure 3.15 Distribution by Phase of Development and Location of Headquarters
Figure 4.1 Distribution by Year of Partnership
Figure 4.2 Distribution by Type of Partnership
Figure 4.3 Distribution by Year and Type of Partnership
Figure 4.4 Distribution by Type of Agreement
Figure 4.5 Distribution by Intercontinental and Intracontinental Deals
Figure 4.6 Distribution by Number of Partnerships
Figure 5.1 Distribution by Annual Instances
Figure 5.2 Distribution of Amount Invested by Year
Figure 5.3 Year-wise Distribution of Instances by Type of Funding
Figure 5.4 Year-wise Distribution of Amount Received and Type of Funding
Figure 5.5 Distribution of Instances by Type of Funding
Figure 5.6 Distribution of Amount Raised by Type of Funding
Figure 5.7 Most Active Investors by Number of Instances
Figure 5.8. Distribution by Number of Instances
Figure 5.9 Distribution by Amount Received
Figure 5.10 Distribution of Amount Raised by Geography
Figure 5.11 Distribution of Amount Raised by Year of Establishment
Figure 5.12 Concluding Remarks
Figure 6.1 Distribution of Grants by Year
Figure 6.2 Distribution of Amount Awarded by Year
Figure 6.3 Key Organizations by Amount Received
Figure 6.4 Distribution by Program Officers
Figure 6.5 Type of Recipient Organization
Figure 6.6 Distribution of Grants by Purpose of Award
Figure 6.7 Distribution by Funding Institute
Figure 6.8 Distribution by Support Period
Figure 6.9 Distribution by Funding Institute and Support Period
Figure 6.10 Distribution by Grant Activity Code
Figure 6.11 Distribution by Type of Application
Figure 6.12 Word Cloud of NIH Spending Categories
Figure 7.1 Benchmarking by Prominent Players
Figure 7.2 Distribution of Developers
Figure 9.1 Distribution of Year of Publication
Figure 9.2 Distribution of Type of Publication
Figure 9.3 Most Popular Journals
Figure 9.4 Most Popular Publisher
Figure 9.5 Distribution by Journal Impact Factor
Figure 9.6 Key Journals by Impact Factor
Figure 9.7 Geographical Distribution of Affiliated Organizations
Figure 9.8 Emerging Focus Areas
Figure 10.1 Cumulative Year-wise Trend of Global Events
Figure 10.2 Distribution by Type of Event
Figure 10.3 Distribution by Type of Platform
Figure 10.4 Leading Players by Number of Participations
Figure 10.5 Leading Presenters by Number of Participations
Figure 10.6 Geographical Distribution of Events
Figure 11.1 Cumulative Year-wise Trend of Tweets
Figure 11.2 Leading Users by Number of Tweets
Figure 11.3 Trending Words / Phrases on Twitter
Figure 12.1 Distribution by Phase of Discontinuation
Figure 12.2 Distribution by Trial Status
Figure 12.3 Distribution by Target Indication
Figure 12.4 Distribution by Route of Administration
Figure 12.5 Distribution by Type of Sponsor
Figure 12.6 Distribution by Affiliated Stakeholders
Figure 12.7 Distribution by Reason for Drug Failure
Figure 12.8 Key Terms in Study Results
Figure 12.9 Other Plausible Reasons for Drug Failure
Figure 14.1 Global NAMPT Inhibitors Market, 2027-2040
Figure 14.2 OT-82: Global Sales Forecast, 2027-2040
Figure 14.3 OT-82: Regional Sales Forecast, 2027-2040
Figure 14.4 ALT-100: Global Sales Forecast, 2029-2040
Figure 14.5 ALT-100: Regional Sales Forecast, 2029-2040
Figure 14.6 ATG-019: Global Sales Forecast, 2030-2040
Figure 14.7 ATG-019: Regional Sales Forecast, 2030-2040
Figure 14.8 KPT-9274: Global Sales Forecast, 2033-2040
Figure 14.9 KPT-9274: Regional Sales Forecast, 2033-2040
Figure 14.10 Distribution by Type of Molecule, 2027-2040
Figure 14.11 Small Molecules: Regional Sales Forecast, 2027-2040
Figure 14.12 Biologics: Regional Sales Forecast, 2029-2040
Figure 14.13 Distribution by Therapeutic Area, 2027-2040
Figure 14.14 Oncological Disorders: Regional Sales Forecast, 2027-2040
Figure 14.15 Respiratory Disorders: Regional Sales Forecast, 2029-2040
Figure 14.16 Distribution by Therapeutic Area, 2027-2040
Figure 14.17 NHL: Regional Sales Forecast, 2027-2035
Figure 14.18 Hodgkin Lymphoma: Regional Sales Forecast, 2027-2040
Figure 14.19 ARDS: Regional Sales Forecast, 2029-2040
Figure 14.20 AML: Regional Sales Forecast, 2033-2040
Figure 14.21 Distribution by Line of Treatment, 2027-2040
Figure 14.22 1st Line Therapies: Regional Sales Forecast, 2027-2040
Figure 14.23 2nd Line Therapies: Regional Sales Forecast, 2033-2040
Figure 14.24 Distribution by Route of Administration, 2027-2040
Figure 14.25 Oral Therapies: Regional Sales Forecast, 2027-20401
Figure 14.26 Intravenous Therapies: Regional Sales Forecast, 2029-2040
Figure 14.27 Market Share of Key Players
Figure 14.28 Distribution by Geography, 2030 and 2040

List Of Tables

Table 3.1 List of Drug Candidates
Table 3.2 List of Drug Developers
Table 4.1 NAMPT Inhibitors: Partnerships and Collaborations
Table 5.1 NAMPT Inhibitors: Funding and Investment
Table 6.1 List of Grants
Table 8.1 Antengene: Funding Information (USD Million)
Table 8.2 Antengene: Product Portfolio
Table 8.3 Antengene: Recent Developments
Table 8.4 Aqualung Therapeutics: Funding Information (USD Million)
Table 8.5 Aqualung Therapeutics: Product Portfolio
Table 8.6 Aqualung Therapeutics: Patent Portfolio
Table 8.7 Aqualung Therapeutics: Recent Developments
Table 8.8 Karyopharm Therapeutics: Financial Information (USD Million)
Table 8.9 Karyopharm Therapeutics: Product Portfolio
Table 8.10 Karyopharm Therapeutics: Patent Portfolio
Table 8.11 Karyopharm Therapeutics: Recent Developments
Table 8.12 OncoTartis: Funding Information (USD Million)
Table 8.13 OncoTartis: Product Portfolio
Table 8.14 OncoTartis: Patent Portfolio
Table 8.15 Onxeo: Financial Information (EUR Million)
Table 8.16 Onxeo: Product Portfolio
Table 8.17 Onxeo: Recent Developments
Table 9.1 NAMPT Inhibitors: List of Publications
Table 10.1 NAMPT Inhibitors: List of Global Events
Table 12.1 NAMPT Inhibitors: List of Failed Drug Candidates
Table 14.1 OT-82: Net Present Value, 2027-2040
Table 14.2 OT-82: Value Creation Analysis, 2027-2040
Table 14.3 ALT-100: Net Present Value, 2029-2040
Table 14.4 ALT-100: Value Creation Analysis, 2029-2040
Table 14.5 ATG-019: Net Present Value, 2030-2040
Table 14.6 ATG-019: Value Creation Analysis, 2030-2040
Table 14.7 KPT-9274: Net Present Value, 2033-2040
Table 14.8 KPT-9274: Value Creation Analysis, 2033-2040

List Of Companies

The following companies and organizations have been mentioned in the report:

  1. 2M Companies
  2. AbbVie
  3. Allakos
  4. Antengene   
  5. Aqualung Therapeutics
  6. Aravive
  7. Aurigene
  8. BioAlliance Pharma
  9. Bioprocess Capital Partners
  10. Boyu Capital
  11. Bpifrance
  12. Calico Life Sciences
  13. Celgene (Acquired by Bristol-Myers Squibb)
  14. Children’s Cancer Institute
  15. Chione
  16. Delphi Ventures
  17. Eli Lilly
  18. Epizyme
  19. European Organization for Research and Treatment of Cancer
  20. Fidelity Management & Research
  21. Financière de la Montagne
  22. Florida International University
  23. Foresite Capital
  24. FountainVest Partners
  25. Fukuoka University
  26. Gemin X (Acquired by Teva Pharmaceuticals)
  27. GIC
  28. Gossamer Bio
  29. GSK
  30. Gustave Roussy
  31. HG
  32. Hillhouse
  33. Indiana University–Purdue University Indianapolis
  34. Invus Public Equities Advisors
  35. Ipsen
  36. Johns Hopkins University
  37. JSR Life Sciences
  38. Karmanos Cancer Institute
  39. Karyopharm Therapeutics 
  40. LeaderMed p
  41. Massachusetts General Hospital
  42. Multiple Myeloma Research Foundation
  43. National Institutes of Health
  44. National Cancer Institute
  45. New Leaf Venture Partners
  46. Newcastle Hospitals
  47. National Heart, Lung, and Blood Institute
  48. National Institute of Aging
  49. National Institute of Diabetes and Digestive and Kidney Diseases
  50. National Institute of Neurological Disorders and Stroke
  51. Norma Investments
  52. Northern Centre for Cancer Care
  53. Novartis
  54. Ohio State University
  55. OncoTartis
  56. Onxeo
  57. Paris-Sud University
  58. Pharmstandard International
  59. Qiming Venture Partners
  60. Robert Wood Johnson Medical School
  61. Rubius Therapeutics
  62. Samuel Oschin Cancer Center
  63. Sanofi
  64. Seattle Genetics
  65. Stanford University Medical School
  66. Taikang Insurance Group
  67. TF Capital
  68. Tigermed
  69. TopoTarget
  70. Tufts University
  71. University of Arizona
  72. University of California Los Angeles
  73. University of Illinois Chicago
  74. University of Missouri
  75. University of Pennsylvania
  76. University of South Florida
  77. University of Southern California
  78. University of Turin
  79. University of Toulouse
  80. University of Utah
  81. University of Wisconsin-Madison
  82. US Oncology Network
  83. UT Southwestern
  84. Valo Health
  85. Veterans Health Administration
  86. Washington University
  87. Wayne State University
  88. WuXi Corporate Venture Fund
  89. Yale University

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 8) n a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com